HeraMED Limited announced it has entered into a commercial agreement with Joondalup Health Campus (JHC) for JHC to offer the HeraCARE solution as the primary standard of care for their entire audience of expecting mothers. This is a major milestone for HeraMED, as it is the first full-scale commercial roll-out of the technology as a standard service to be offered to all suitable pregnant mothers by a hospital. HeraMED began working collaboratively with JHC in 2020 through a clinical trial that delivered clinical and functional validation of the HeraBEAT device which forms the backbone of the HeraCARE solution.

The accuracy of the HeraBEAT device was found to be excellent when compared to the industry gold standard CTG (Phillips Avalon) machine. The Foetal Heart Rate (FHR) was detected on 100% of occasions by clinicians, and importantly, the FHR was detected on 100% of occasions by the expectant mothers when using the device without assistance. On completion of the clinical trial and publication of the results in the globally renowned `Green Journal', the leading scientific journal for gynaecology and obstetrics, HeraMED and JHC undertook a paid pilot of the HeraCARE platform.

The pilot focused on ensuring the HeraCARE platform was fully integrated with the existing workflows and clinical pathways. Parties focused on configuring and optimising the platform to accommodate JHC's requirements, as well as providing training to key stakeholders in the pilots, including midwives, clinicians, obstetricians, and expecting mothers. The paid pilot represented the last stage of the collaboration to incorporate the HeraCARE platform to introduce remote monitoring and care management for pregnant women.

Interim results of this pilot were released in early December 2021 and were very positive. The pilot had demonstrated exceptional user satisfaction from expectant mothers as well as midwives and clinicians, with stakeholders endorsing this remote monitoring solution as part of a new standard of care for pregnancy. The interim results provided confidence for JHC and HMD to reach a commercial agreement of a full rollout of the HeraCARE solution within JHC.